Build Your Comparison

Side-by-side financial analysis
ORGN logo
ORGN
VVOS logo
VVOS
JPM logo
JPM
BAC logo
BAC
ALGN logo
ALGN
Try popular comparisons:

Stock Comparison

ORGN vs VVOS vs JPM vs BAC vs ALGN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ORGN
Origin Materials, Inc.

Chemicals

Basic MaterialsNASDAQ • US
Market Cap$6M
5Y Perf.-99.7%
VVOS
Vivos Therapeutics, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$3M
5Y Perf.-99.7%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$908.57B
5Y Perf.+155.9%
BAC
Bank of America Corporation

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$424.14B
5Y Perf.+85.4%
ALGN
Align Technology, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$13.04B
5Y Perf.-65.9%

ORGN vs VVOS vs JPM vs BAC vs ALGN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ORGN logoORGN
VVOS logoVVOS
JPM logoJPM
BAC logoBAC
ALGN logoALGN
IndustryChemicalsMedical - DevicesBanks - DiversifiedBanks - DiversifiedMedical - Devices
Market Cap$6M$3M$908.57B$424.14B$13.04B
Revenue (TTM)$14M$20M$280.33B$191.57B$4.10B
Net Income (TTM)$-241M$-25M$57.05B$30.51B$430M
Gross Margin-4.4%59.5%60.0%56.1%67.7%
Operating Margin-459.3%-115.5%25.9%19.7%14.4%
Forward P/E14.6x12.6x16.0x
Total Debt$28M$14M$942.38B$365.90B$114M
Cash & Equiv.$33M$2M$343.34B$231.84B$1.08B

ORGN vs VVOS vs JPM vs BAC vs ALGNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ORGN
VVOS
JPM
BAC
ALGN
StockDec 20Jun 26Return
Origin Materials, I… (ORGN)1000.3-99.7%
Vivos Therapeutics,… (VVOS)1000.3-99.7%
JPMorgan Chase & Co. (JPM)100255.9+155.9%
Bank of America Cor… (BAC)100185.4+85.4%
Align Technology, I… (ALGN)10034.1-65.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: ORGN vs VVOS vs JPM vs BAC vs ALGN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: VVOS and JPM are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. JPMorgan Chase & Co. is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. BAC and ALGN also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
ORGN
Origin Materials, Inc.
The Defensive Pick

ORGN is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.54, Low D/E 26.6%, current ratio 2.83x
Best for: sleep-well-at-night
VVOS
Vivos Therapeutics, Inc.
The Growth Play

VVOS has the current edge in this matchup, primarily because of its strength in growth exposure.

  • Rev growth 16.0%, EPS growth 7.2%, 3Y rev CAGR 2.9%
  • 16.0% revenue growth vs ORGN's -39.5%
  • Beta 0.51 vs ALGN's 1.61
Best for: growth exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the #2 pick in this set and the best alternative if long-term compounding and bank quality is your priority.

  • 481.2% 10Y total return vs BAC's 371.6%
  • NIM 2.2% vs BAC's 1.8%
  • 20.4% margin vs ORGN's -17.2%
  • 1.8% yield, 15-year raise streak, vs BAC's 2.3%, (3 stocks pay no dividend)
Best for: long-term compounding and bank quality
BAC
Bank of America Corporation
The Banking Pick

BAC ranks third and is worth considering specifically for income & stability and valuation efficiency.

  • Dividend streak 12 yrs, beta 0.83, yield 2.3%
  • PEG 0.82 vs JPM's 0.83
  • Beta 0.83, yield 2.3%, current ratio 0.42x
  • Lower P/E (12.6x vs 16.0x)
Best for: income & stability and valuation efficiency
ALGN
Align Technology, Inc.
The Niche Pick

ALGN is the clearest fit if your priority is efficiency.

  • 6.9% ROA vs ORGN's -99.5%, ROIC 15.4% vs -24.4%
Best for: efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthVVOS logoVVOS16.0% revenue growth vs ORGN's -39.5%
ValueBAC logoBACLower P/E (12.6x vs 16.0x)
Quality / MarginsJPM logoJPM20.4% margin vs ORGN's -17.2%
Stability / SafetyVVOS logoVVOSBeta 0.51 vs ALGN's 1.61
DividendsJPM logoJPM1.8% yield, 15-year raise streak, vs BAC's 2.3%, (3 stocks pay no dividend)
Momentum (1Y)BAC logoBAC+27.2% vs ORGN's -91.8%
Efficiency (ROA)ALGN logoALGN6.9% ROA vs ORGN's -99.5%, ROIC 15.4% vs -24.4%

ORGN vs VVOS vs JPM vs BAC vs ALGN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ORGNOrigin Materials, Inc.
FY 2025
Product
100.0%$19M
VVOSVivos Therapeutics, Inc.
FY 2025
Service
43.3%$11M
Product
25.6%$6M
Appliances
13.0%$3M
Treatment Centers
8.6%$2M
Sponsorship Seminar Other
4.8%$1M
Billing Intelligence Services
2.7%$686,000
VIP
1.9%$491,000
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000
BACBank of America Corporation
FY 2024
Loans and Leases
32.2%$62.0B
other interest income
14.7%$28.3B
Debt securities
13.5%$26.0B
Federal funds sold and securities borrowed or purchased under agreements to resell
10.3%$19.9B
Investment And Brokerage Services
9.2%$17.8B
Market making and similar activities
6.7%$13.0B
Trading account assets
5.4%$10.4B
Other (4)
7.8%$15.1B
ALGNAlign Technology, Inc.
FY 2025
Clear Aligner
80.4%$3.2B
Scanners And Services
19.6%$790M

ORGN vs VVOS vs JPM vs BAC vs ALGN — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGBAC

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 20068.2x ORGN's $14M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ORGN's -17.2%. On growth, VVOS holds the edge at +70.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricORGN logoORGNOrigin Materials,…VVOS logoVVOSVivos Therapeutic…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ALGN logoALGNAlign Technology,…
RevenueTrailing 12 months$14M$20M$280.3B$191.6B$4.1B
EBITDAEarnings before interest/tax-$55M-$21M$81.4B$40.0B$790M
Net IncomeAfter-tax profit-$241M-$25M$57.0B$30.5B$430M
Free Cash FlowCash after capex-$59M-$18M$100.9B$12.6B$717M
Gross MarginGross profit ÷ Revenue-4.4%+59.5%+60.0%+56.1%+67.7%
Operating MarginEBIT ÷ Revenue-4.6%-115.5%+25.9%+19.7%+14.4%
Net MarginNet income ÷ Revenue-17.2%-128.4%+20.4%+15.9%+10.5%
FCF MarginFCF ÷ Revenue-4.3%-93.3%+36.0%+6.6%+17.5%
Rev. Growth (YoY)Latest quarter vs prior year-91.2%+70.5%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+39.3%-15.6%+16.0%+18.3%+23.6%
JPM leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — VVOS and JPM and BAC each lead in 2 of 7 comparable metrics.

At 14.7x trailing earnings, BAC trades at a 54% valuation discount to ALGN's 32.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs BAC's 0.96x — a lower PEG means you pay less per unit of expected earnings growth.

MetricORGN logoORGNOrigin Materials,…VVOS logoVVOSVivos Therapeutic…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ALGN logoALGNAlign Technology,…
Market CapShares × price$6M$3M$908.6B$424.1B$13.0B
Enterprise ValueMkt cap + debt − cash$781,018$14M$1.51T$558.2B$12.1B
Trailing P/EPrice ÷ TTM EPS-0.02x-0.24x16.22x14.71x32.23x
Forward P/EPrice ÷ next-FY EPS est.14.60x12.60x16.01x
PEG RatioP/E ÷ EPS growth rate0.92x0.96x
EV / EBITDAEnterprise value multiple18.52x13.95x15.15x
Price / SalesMarket cap ÷ Revenue0.32x0.17x3.25x2.21x3.23x
Price / BookPrice ÷ Book value/share0.05x2.51x1.40x3.26x
Price / FCFMarket cap ÷ FCF9.01x33.63x26.57x
Evenly matched — VVOS and JPM and BAC each lead in 2 of 7 comparable metrics.

Profitability & Efficiency

ALGN leads this category, winning 7 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-23 for VVOS. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BAC scores 7/9 vs VVOS's 2/9, reflecting strong financial health.

MetricORGN logoORGNOrigin Materials,…VVOS logoVVOSVivos Therapeutic…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ALGN logoALGNAlign Technology,…
ROE (TTM)Return on equity-120.7%-23.4%+15.9%+10.1%+10.7%
ROA (TTM)Return on assets-99.5%-98.6%+1.3%+0.9%+6.9%
ROICReturn on invested capital-24.4%-2.3%+4.5%+3.5%+15.4%
ROCEReturn on capital employed-25.7%-2.3%+8.9%+4.5%+14.5%
Piotroski ScoreFundamental quality 0–932577
Debt / EquityFinancial leverage0.27x2.60x1.21x0.03x
Net DebtTotal debt minus cash-$5M$11M$599.0B$134.1B-$965M
Cash & Equiv.Liquid assets$33M$2M$343.3B$231.8B$1.1B
Total DebtShort + long-term debt$28M$14M$942.4B$365.9B$114M
Interest CoverageEBIT ÷ Interest expense-2627.81x0.74x0.48x389.13x
ALGN leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $37 for ORGN. Over the past 12 months, BAC leads with a +27.2% total return vs ORGN's -91.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs ORGN's -79.4% — a key indicator of consistent wealth creation.

MetricORGN logoORGNOrigin Materials,…VVOS logoVVOSVivos Therapeutic…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ALGN logoALGNAlign Technology,…
YTD ReturnYear-to-date-84.6%-80.2%+0.8%+1.4%+16.7%
1-Year ReturnPast 12 months-91.8%-79.8%+20.9%+27.2%+1.1%
3-Year ReturnCumulative with dividends-99.1%-96.1%+138.8%+105.5%-45.1%
5-Year ReturnCumulative with dividends-99.6%-99.6%+135.5%+57.4%-69.7%
10-Year ReturnCumulative with dividends-99.6%-99.8%+481.2%+371.6%+128.5%
CAGR (3Y)Annualised 3-year return-79.4%-66.0%+33.7%+27.1%-18.1%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — VVOS and BAC each lead in 1 of 2 comparable metrics.

VVOS is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than ALGN's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 96.9% from its 52-week high vs ORGN's 3.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricORGN logoORGNOrigin Materials,…VVOS logoVVOSVivos Therapeutic…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ALGN logoALGNAlign Technology,…
Beta (5Y)Sensitivity to S&P 5001.54x0.51x0.87x0.83x1.61x
52-Week HighHighest price in past year$28.49$7.95$338.09$57.98$208.31
52-Week LowLowest price in past year$0.20$0.45$269.72$44.21$122.00
% of 52W HighCurrent price vs 52-week peak+3.8%+6.3%+96.2%+96.9%+87.4%
RSI (14)Momentum oscillator 0–10033.634.272.170.951.9
Avg Volume (50D)Average daily shares traded563K299K7.4M32.4M915K
Evenly matched — VVOS and BAC each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.

Analyst consensus: ORGN as "Buy", JPM as "Buy", BAC as "Buy", ALGN as "Buy". Consensus price targets imply 8156.9% upside for ORGN (target: $90) vs 4.5% for JPM (target: $340). For income investors, BAC offers the higher dividend yield at 2.25% vs JPM's 1.83%.

MetricORGN logoORGNOrigin Materials,…VVOS logoVVOSVivos Therapeutic…JPM logoJPMJPMorgan Chase & …BAC logoBACBank of America C…ALGN logoALGNAlign Technology,…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$90.00$339.75$61.13$203.60
# AnalystsCovering analysts6615433
Dividend YieldAnnual dividend ÷ price+1.8%+2.3%
Dividend StreakConsecutive years of raises11512
Dividend / ShareAnnual DPS$5.95$1.27
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.8%+5.1%+3.6%
Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.
Key Takeaway

JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ALGN leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 2 of 6 categories
Loading custom metrics...

ORGN vs VVOS vs JPM vs BAC vs ALGN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ORGN or VVOS or JPM or BAC or ALGN a better buy right now?

For growth investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger pick with 16. 0% revenue growth year-over-year, versus -39. 5% for Origin Materials, Inc. (ORGN). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ORGN or VVOS or JPM or BAC or ALGN?

On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.

7x versus Align Technology, Inc. at 32. 2x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 82x versus JPMorgan Chase & Co. 's 0. 83x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — ORGN or VVOS or JPM or BAC or ALGN?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -99. 6% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: JPM returned +481. 2% versus VVOS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ORGN or VVOS or JPM or BAC or ALGN?

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 51β versus Align Technology, Inc. 's 1. 61β — meaning ALGN is approximately 217% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ORGN or VVOS or JPM or BAC or ALGN?

By revenue growth (latest reported year), Vivos Therapeutics, Inc.

(VVOS) is pulling ahead at 16. 0% versus -39. 5% for Origin Materials, Inc. (ORGN). On earnings-per-share growth, the picture is similar: Bank of America Corporation grew EPS 18. 6% year-over-year, compared to -188. 2% for Origin Materials, Inc.. Over a 3-year CAGR, VVOS leads at 2. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ORGN or VVOS or JPM or BAC or ALGN?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -1319. 6% for Origin Materials, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -335. 4% for ORGN. At the gross margin level — before operating expenses — ALGN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ORGN or VVOS or JPM or BAC or ALGN more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 82x versus JPMorgan Chase & Co. 's 0. 83x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 16. 0x for Align Technology, Inc. — 3. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORGN: 8156. 9% to $90. 00.

08

Which pays a better dividend — ORGN or VVOS or JPM or BAC or ALGN?

In this comparison, BAC (2.

3% yield), JPM (1. 8% yield) pay a dividend. ORGN, VVOS, ALGN do not pay a meaningful dividend and should not be held primarily for income.

09

Is ORGN or VVOS or JPM or BAC or ALGN better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, ORGN: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ORGN and VVOS and JPM and BAC and ALGN?

These companies operate in different sectors (ORGN (Basic Materials) and VVOS (Healthcare) and JPM (Financial Services) and BAC (Financial Services) and ALGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ORGN is a small-cap quality compounder stock; VVOS is a small-cap high-growth stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; ALGN is a mid-cap quality compounder stock. JPM, BAC pay a dividend while ORGN, VVOS, ALGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.